Upcoming Financial Results Announcement by Pharming Group
Pharming Group N.V. (NASDAQ: PHAR) is gearing up to share its preliminary financial results for the fourth quarter and the full year of 2024. The crucial date for this announcement is set for March 13, 2025. The company will provide insights into its financial performance for the period that concluded on December 31, 2024.
Investor Presentation Details
On the same day, Pharming will host a presentation aimed at analysts and investors. This presentation is scheduled to commence at 13:30 CET or 08:30 AM EDT, allowing stakeholders to gain a deeper understanding of the company's results.
How to Participate
Interested parties looking to participate in the conference call are encouraged to register in advance. Upon registration, participants will receive dial-in details along with a unique PIN to access the call. It is important to note that questions will be entertained only from dial-in attendees.
Live Webcast Information
For those who prefer to watch the presentation live, Pharming will also provide a webcast. Similar to the conference call, registration is required to access the webcast. This initiative ensures that more individuals can engage with the company’s vital updates.
About Pharming Group N.V.
Pharming Group N.V. (NASDAQ: PHAR) is dedicated to enhancing the lives of patients afflicted with rare and severe diseases. The company's mission is reflected in its innovative portfolio of protein replacement therapies and precision medicines, which encompass both small molecules and biologics. With a global presence, Pharming operates out of Leiden, the Netherlands, and supports patients across over 30 markets in regions such as North America, Europe, and Asia-Pacific.
Global Reach and Impact
Pharming's commitment to delivering groundbreaking treatments showcases its role as a leader in the biopharmaceutical industry. By continuously striving for innovation and excellence, the company aims to address unmet medical needs for patients facing challenging health conditions.
Recent Developments
Throughout the past year, Pharming has made significant strides in advancing its product offerings and enhancing its market reach. The company remains focused on leveraging its research and development efforts to foster growth and innovation in the biopharmaceutical landscape.
Contact Information
For any public inquiries, Pharming Group can be reached through various channels:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Frequently Asked Questions
When will Pharming report its 2024 financial results?
Pharming will report its 2024 preliminary financial results on March 13, 2025.
What time is the investor presentation scheduled?
The investor presentation is set for 13:30 CET/08:30 AM EDT on the same day.
How can I participate in the conference call?
You need to register in advance to obtain the dial-in information and unique PIN for the call.
Will there be a live webcast available?
Yes, Pharming will provide a live webcast, but registration is required to access it.
What is Pharming Group's primary focus?
Pharming Group is focused on developing and commercializing innovative treatments for patients with rare and life-threatening diseases.
